Bergen, Norway, 28 April 2022 - Annual general meeting of BerGenBio ASA was virtually held today 28 April 2022 at 10.00 CET.

All proposals were resolved as presented in the notice convening the annual general meeting distributed on 7 April 2022, as further set out in the minutes from the annual general meeting attached hereto and available at https://www.bergenbio.com/investors/general-meetings/.

For further information, please contact:

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.